AIMS: TAVI is a minimally invasive alternative to surgical aortic valve replacement or medical therapy in patients with a high or prohibitive operative risk. The clinical significance of baseline anemia and prognostic implications in this patient cohort are unknown. We sought to evaluate the prevalence and prognostic implications of baseline anaemia in patients undergoing transcatheter aortic valve implantation (TAVI) at our institution. METHODS AND RESULTS: One hundred and eighteen consecutive patients who underwent TAVI with the Medtronic Corevalve System (Medtronic Corp., Minneapolis, MN, USA) were included in the analysis. Clinical and biochemical data were prospectively collected before, during and after the procedure. Clinical follow-up was set at one month, one year and yearly thereafter. Anaemia was defined as a haemoglobin level <13 g/dL in men and <12 g/dL in women. Mortality was confirmed by consultation of the civil registry. The prevalence of baseline anaemia was 49%. Anaemic patients undergoing TAVI required more RBC transfusions (3.3 ± 3.1 versus 1.5 ± 2.3; p<0.001) and more frequently experienced a prolonged index hospitalisation exceeding two weeks. For patients with at least 1-year follow up (N=74), mortality at 30 days was no different; however 1-year mortality was significantly higher in the anaemic cohort (44 versus 15%, p=0.006). In a multivariable analysis, baseline anaemia emerged as an independent predictor of 1- year mortality (HR 2.10 [1.06-4.18]). CONCLUSIONS: In our series, baseline anaemia is common in patients undergoing TAVI, forecasts a need for more red blood cell transfusions and is associated with increased 1-year mortality.
AIMS: TAVI is a minimally invasive alternative to surgical aortic valve replacement or medical therapy in patients with a high or prohibitive operative risk. The clinical significance of baseline anemia and prognostic implications in this patient cohort are unknown. We sought to evaluate the prevalence and prognostic implications of baseline anaemia in patients undergoing transcatheter aortic valve implantation (TAVI) at our institution. METHODS AND RESULTS: One hundred and eighteen consecutive patients who underwent TAVI with the Medtronic Corevalve System (Medtronic Corp., Minneapolis, MN, USA) were included in the analysis. Clinical and biochemical data were prospectively collected before, during and after the procedure. Clinical follow-up was set at one month, one year and yearly thereafter. Anaemia was defined as a haemoglobin level <13 g/dL in men and <12 g/dL in women. Mortality was confirmed by consultation of the civil registry. The prevalence of baseline anaemia was 49%. Anaemic patients undergoing TAVI required more RBC transfusions (3.3 ± 3.1 versus 1.5 ± 2.3; p<0.001) and more frequently experienced a prolonged index hospitalisation exceeding two weeks. For patients with at least 1-year follow up (N=74), mortality at 30 days was no different; however 1-year mortality was significantly higher in the anaemic cohort (44 versus 15%, p=0.006). In a multivariable analysis, baseline anaemia emerged as an independent predictor of 1- year mortality (HR 2.10 [1.06-4.18]). CONCLUSIONS: In our series, baseline anaemia is common in patients undergoing TAVI, forecasts a need for more red blood cell transfusions and is associated with increased 1-year mortality.
Authors: R J Nuis; A E Dager; R M van der Boon; M C Jaimes; B Caicedo; J Fonseca; N M Van Mieghem; L M Benitez; J P Umana; W W O'Neill; E de Marchena; P P de Jaegere Journal: Neth Heart J Date: 2012-01 Impact factor: 2.380
Authors: Katarzyna Czerwińska-Jelonkiewicz; Adam Witkowski; Maciej Dąbrowski; Marek Banaszewski; Ewa Księżycka-Majczyńska; Zbigniew Chmielak; Krzysztof Kuśmierski; Tomasz Hryniewiecki; Marcin Demkow; Ewa Orłowska-Baranowska; Janina Stępińska Journal: Arch Med Sci Date: 2013-12-26 Impact factor: 3.318
Authors: Silvia Mas-Peiro; Philipp C Seppelt; Roberta De Rosa; Marie-Isabel Murray; Jörg Yogarajah; Alexander Berkowitsch; Stephan Fichtlscherer; Andreas M Zeiher; Mariuca Vasa-Nicotera Journal: Front Cardiovasc Med Date: 2020-11-30
Authors: V J Nijenhuis; P R Stella; J Baan; B R G Brueren; P P de Jaegere; P den Heijer; S H Hofma; P Kievit; T Slagboom; A F M van den Heuvel; F van der Kley; L van Garsse; K G van Houwelingen; A W J Van't Hof; J M Ten Berg Journal: Neth Heart J Date: 2014-02 Impact factor: 2.380
Authors: M S van Mourik; J F Velu; V R Lanting; J Limpens; B J Bouma; J J Piek; J Baan; J P S Henriques; M M Vis Journal: Neth Heart J Date: 2020-05 Impact factor: 2.380
Authors: Kush P Patel; Thomas A Treibel; Paul R Scully; Michael Fertleman; Samuel Searle; Daniel Davis; James C Moon; Michael J Mullen Journal: Interv Cardiol Date: 2022-01-18